CRNX Stock Forecast & Price Target

Crinetics Pharmaceuticals Inc. has demonstrated a notable increase in revenue expectations for its flagship product, Palsonify, with 2026 revenue estimates rising from $49 million to $62 million following a robust performance that exceeded previous forecasts. The company reported over $5 million in net product revenue for Palsonify in the fourth quarter of 2025, outperforming both consensus estimates and prior projections, indicating strong market traction and physician adoption. Additionally, with a positive early experience reported by approximately 30% of prescribing endocrinologists, Crinetics is well-positioned for continued growth, particularly as it advances its pipeline candidates towards pivotal clinical milestones.

Crinetics Pharmaceuticals faces significant headwinds as observations of liver enzyme elevations pose a near-term overhang for the market potential of its lead product, Palsonify, which is unable to differentiate itself sufficiently from existing therapies. The company is projected to continue incurring net losses through the commercialization phase, raising concerns over cash flow sustainability amidst significant financial risks. Furthermore, the reduction of peak sales estimates in the EU by 40% undermines expectations for revenue generation, compounded by the uncertainties surrounding clinical trial outcomes, regulatory approvals, and increasing competition in the market.